

Table of Contents

ARNE ASTRUP, PROJECT DIRECTOR, PROFESSOR	1
NOVO NORDISK FOUNDATION	1
ANDREW HATTERSLEY, PROFESSOR	1
UNIVERSITY OF EXETER	1
BETTINA LUNDGREN, CEO	2
DANISH NATIONAL GENOME CENTER	2
CARLA GREENBAUM, DIRECTOR	2
BENAROYA RESEARCH INSTITUTE	2
CAROLINE BONNER, DR.	3
INSTITUT PASTEUR DE LILLE	3
CHANTAL MATHIEU, PROFESSOR	3
KATHOLIEKE UNIVERSITEIT LEUVEN	3
CHARLOTTE LING, PROFESSOR	4
LUND UNIVERSITY	4
CHRISTIAN COLLIN, PERSON WITH DIABETES	4
STENO DIABETES CENTER COPENHAGEN	4
DANIEL R. WITTE, PROFESSOR	5
STENO DIABETES CENTER AARHUS	5
ERAN SEGAL, PROFESSOR	5
WEIZMANN INSTITUTE OF SCIENCE	5
EWAN PEARSON, PROFESSOR	6
UNIVERSITY OF DUNDEE	6
GILES YEO, DR.	6
UNIVERSITY OF CAMBRIDGE	6
HENRIK ULLUM, CEO	6
STATENS SERUM INSTITUT	6
HINDRIK MULDER, EDITOR-IN-CHIEF, PROFESSOR	7

DIABETOLOGIA, LUND UNIVERSITY	7
SIR JOHN BELL, PROFESSOR	8
OFFICE FOR THE STRATEGIC COORDINATION OF HEALTH RESEARCH	8
JOSE C. FLOREZ, PROFESSOR	8
HARVARD MEDICAL SCHOOL	8
JULEEN R. ZIERATH, PROFESSOR	9
KAROLINSKA INSTITUTET AND UNIVERSITY OF COPENHAGEN	9
KARI STEFANSSON, CEO	10
DECODE	10
LOUIS H. PHILIPSON, PROFESSOR	10
UNIVERSITY OF CHICAGO	10
MADS KROGSGAARD THOMSEN, CEO	11
NOVO NORDISK FOUNDATION	11
MARIA F. GOMEZ, PROFESSOR	12
LUND UNIVERSITY	12
MARIE-FRANCE HIVERT, ASSOCIATE PROFESSOR	12
HARVARD MEDICAL SCHOOL	12
MARIT EIKA JØRGENSEN, PROFESSOR	13
STENO DIABETES CENTER GREENLAND	13
MARTIN RIDDERSTRÅLE, SENIOR VICE PRESIDENT	13
NOVO NORDISK FOUNDATION	13
MICHAEL LYNGE PEDERSEN, CHIEF MEDICAL OFFICER.	14
STENO DIABETES CENTER GREENLAND	14
MICHAEL RODEN, PROFESSOR	14
HEINRICH-HEINE UNIVERSITY, EFSD SCIENTIFIC BOARD	14
MIRIAM S. UDLER, ASSISTANT PROFESSOR	15
HARVARD MEDICAL SCHOOL	15
NYNNE BJERRE CHRISTENSEN, JOURNALIST	16
FREELANCE	16

PAUL W. FRANKS, SCIENTIFIC DIRECTOR, PROFESSOR	16
NOVO NORDISK FOUNDATION	16
RONALD MA, PROFESSOR	17
CHINESE UNIVERSITY OF HONG KONG	17
RUTH LOOS, PROFESSOR	17
UNIVERSITY OF COPENHAGEN	17
STEFANO DEL PRATO, PRESIDENT	18
THE EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES	18
SIR STEPHEN O'RAHILLY, PROFESSOR	18
UNIVERSITY OF CAMBRIDGE	18
SØREN BRUNAK, PROFESSOR	19
UNIVERSITY OF COPENHAGEN	19
TINA BLICHFELDT, PERSON WITH DIABETES	19
STENO DIABETES CENTER COPENHAGEN	19
TORBEN HANSEN, PROFESSOR	20
UNIVERSITY OF COPENHAGEN	20
THOMAS R. PIEBER, PROFESSOR	21
MEDICAL UNIVERSITY OF GRAZ	21

Arne Astrup, Project Director, Professor

Novo Nordisk Foundation

Arne Astrup is a medical doctor (1981) with a doctoral thesis in medicine (DMSc, 1986), and Professor (1990) from the University of Copenhagen (DK). He is one of the University of Copenhagen's most cited researchers and internationally recognised. He undertakes basic, physiological, and clinical research in appetite and energy metabolism, with an aim to improving the prevention and treatment of obesity and related diseases. Under his leadership, the Department of Nutrition, Exercise and Sports ranked as the world's number one sports and nutrition research environment in the internationally recognised *Shanghai Ranking's* 2018 Global Ranking of Sport Science Schools and Departments.

He has been awarded numerous prizes and has also served as an adviser to several companies regarding nutrition and obesity, as well as being a co-founder of companies. He was elected Knight of the Order of Dannebrog in 1999 and Knight of the First Order of Dannebrog in November 2012, for his services to science. He was the founding Editor-in-Chief of *Obesity Reviews* from 1999 through 2010, as well as President of The International Association for the Study of Obesity (IASO), 2006–2009, and Chairman, 2009–2010. Currently he is Associate Editor of *American Journal of Clinical Nutrition*. Since 2020 he has been Project Director at the Novo Nordisk Foundation, with primary responsibility for the development and establishment of a new national centre for the promotion of healthy weight through collaborative research, innovation and the development of evidence-based interventions and prevention efforts, with a special focus on children and their families.

Andrew Hattersley, Professor

University of Exeter

Andrew Hattersley is a Professor of Molecular Medicine at the University of Exeter (UK) and is known for his research in monogenic diabetes. He was elected a Fellow of the Royal Society in 2010 and his work combines clinical observations, cutting edge molecular genetics and in depth clinical and physiological studies. Professor Hattersley has described 12 new subtypes of monogenic diabetes and developed diagnostic and treatment approaches for monogenic diabetes that are adopted throughout the world.

Professor Hattersley became Gillings Chair in Precision Medicine in 2015 and leads the Precision medicine initiative in Exeter working with both scientific and clinical colleagues. Professor Hattersley has played a major role in the UK research effort into the genetics of type 2 diabetes, and he continues to work as a consultant physician in diabetes while at the same time leading a large research team. His research combines

state-of-the-art molecular genetics with physiological and clinical investigations in patients and he uses the accidents of nature that cause monogenic diabetes to understand the critical role of the gene product in man, in a similar fashion to many laboratory scientists who study animals. A key theme of his approach is that his scientific discoveries are rapidly and effectively translated into improvements in clinical care.

Bettina Lundgren, CEO

Danish National Genome Center

Bettina Lundgren is CEO of the Danish National Genome Center. The Danish National Genome Center supports physicians and researchers in using knowledge on patients' genes and new technology to develop personalized medicine. CEO Lundgren leads the further development of the centre, where emphasis is placed on the centre's work to benefit the individual patient and to promote international and national research in personal medicine in the Danish healthcare system.

CEO Lundgren is a specialist in Clinical Microbiology and a Doctor of Medicine from the University of Copenhagen. Since 2010, she has been centre director for more than 1,600 employees at the Diagnostic Center at Rigshospitalet. CEO Lundgren has in-depth knowledge of the Danish healthcare system and extensive experience from several clinical departments. She has more than 19 years of management experience from the health service as well as broad research experience from several employments both at home and abroad, including the US National Institutes of Health (NIH).

Carla Greenbaum, Director

Benaroya Research Institute

Carla Greenbaum is a clinical investigator and director who works to alter the course of type 1 diabetes through understanding the causes of disease, and testing interventions to alter immune mediated beta cell dysfunction. After receiving a medical degree at Brown University, Director Greenbaum completed her endocrinology fellowship at the University of Washington. She joined the Benaroya Research Institute (US) in 2000, serving as a Member and as Director of the Diabetes Research Program and the Benaroya Research Institute Clinical Research Center. She serves on the Board of Directors for Benaroya Research Institute and is a member of the Benaroya Research Institute Institutional Review Board, which provides oversight for clinical studies. Furthermore, she is Chair of Type 1 Diabetes TrialNet, an NIH sponsored international consortium to test disease modifying therapies in T1D. Director Greenbaum is on the Scientific Review Committee for the Diabetes Vaccine Development Center (Australia), the Clinical Affairs Advisory Committee for the Juvenile Diabetes Research Foundation (JDRF), the Diabetes Group of the NIH sponsored Immune Tolerance

Network, as well as serving on other NIH, JDRF, and American Diabetes Association (ADA) editorial and DSMB review committees.

Caroline Bonner, Dr.

Institut Pasteur de Lille

Dr. Caroline Bonner completed her Ph.D. studies in 2009 from the Royal College of Surgeons in Dublin, Ireland, which focused on the differentiation and regeneration of pancreatic beta cells using genetic models of Maturity onset-diabetes of the young (MODY). She pursued a post-doctoral fellow in translational medicine in the same laboratory (2009-2011), focusing on the discovery and validation of serum biomarkers (microRNAs and secreted proteins) in MODY patients as well as in type 1 diabetic and type 2 diabetic subjects. In 2012, she joined Inserm unit 1190 - Translational Research for Diabetes, at The University of Lille, on a post-doctoral fellowship to pursue an independent research project on insulin-independent regulation of glucagon secretion with and without current drug therapies using human islets ex-vivo and mouse models of diabetes. She is currently a group leader at Institut Pasteur de Lille (FR) continuing in deciphering the mechanisms by which antihyperglycemic drugs regulate glucose homeostasis and normalize pancreatic hormone secretion in both monogenic and polygenic forms of diabetes.

Chantal Mathieu, Professor

Katholieke Universiteit Leuven

Chantal Mathieu is Professor of Medicine and Program Director of Biomedical Sciences at the Katholieke Universiteit Leuven (B). Furthermore, she is Chair of Endocrinology at the University Hospital Gasthuisberg Leuven. Professor Mathieu received her medical degree and PhD at the University of Leuven, where she subsequently completed training in internal medicine and endocrinology.

Professor Mathieu's clinical areas of interest include the organization of diabetes care, and she is involved in several clinical trials in type 1 and type 2 diabetes. Professor Mathieu's basic research is focused on the prevention of type 1 diabetes, effects of vitamin D on the immune system and diabetes and functioning of the insulin-producing beta cell. In 2013, Professor Mathieu received the prestigious InBev-Baillet Latour Prize for Clinical Research for her pioneering research on the pathogenesis of type 1 diabetes. Professor Mathieu is a member of the editorial board for the Journal of Diabetes and its Complications and is a past associate editor and advisory board member of Diabetologia. Professor Mathieu presently coordinates the INNODIA project on prevention and intervention in type 1 diabetes in Europe. Furthermore, Professor Mathieu is vice-president of European Association for the Study of Diabetes.

Charlotte Ling, Professor

Lund University

Charlotte Ling is a Professor at Lund University (S) and a principal investigator of the Epigenetics and Diabetes Unit at the Lund University Diabetes Centre (LUDC). She obtained her PhD in Endocrinology in 2002. After a postdoc at Lund University, where she studied genetics of type 2 diabetes, she dedicated her research to the study of epigenetic mechanisms causing type 2 diabetes and metabolic disease. Her research group has over the last 17 years pioneered the field of epigenetics in type 2 diabetes. They have made numerous ground-breaking discoveries such as genome-wide epigenetic modifications in pancreatic islets, skeletal muscle, adipose tissue and the liver from patients with type 2 diabetes compared with non-diabetic controls. Her group has also shown that genetic and non-genetic factors such as SNPs, exercise, diet, obesity and age alter the genome-wide epigenetic pattern in key human tissues affecting type 2 diabetes. She has been awarded numerous research grants and awards from for example the Swedish Research Council, European Commission (ERC and H2020), Novo Nordisk Distinguished Investigator Grant and EFSD/NNF Precision Diabetes Medicine runner-up award

Christian Collin, Person with diabetes

Steno Diabetes Center Copenhagen

Christian Collin is a chief pilot in the Danish aviation industry as well as a flight instructor and examiner. Furthermore, Christian Collin is partner in MA&P, a consulting company in the aviation and healthcare sector that provides analysis, support and advisory based on experience in the operational environment of commercial aviation.

Christian Collin was in 2017 diagnosed with diabetes type 1.5, a subtype of type 1 diabetes also known as LADA. He is a user of the Steno Diabetes Center Copenhagen, which offers world-class treatment in diabetes in Denmark. Based on his relation to the Steno Diabetes Center Copenhagen, he became a member of the Steno Diabetes Center Copenhagen's Board of Directors in 2019 as a user representative. User representation in the Board of Directors is an initiative in connection with Steno Diabetes Center Copenhagen's intensified focus on user involvement which aims to strengthen the Center in decision-making and development processes. Christian Collin contributes with the user perspective on different topics ranging from research to economics and construction of new facilities. His focus as a board member is especially on the mental aspects of living with diabetes and how the diagnosis can change the patient's life dramatically. Therefore, he aims to create more opportunities for diabetic patients to share knowledge and exchange experiences with each other.

Daniel R. Witte, Professor

Steno Diabetes Center Aarhus

Daniel R. Witte is Professor in Diabetes Epidemiology at the Department of Public Health, Aarhus University (DK) and Steno Diabetes Center Aarhus (DK). Professor Witte's main research interest is studying the pathophysiological mechanisms that determine the transition from normal glucose control via pre-diabetes to diabetes and the early stages of its complications, at the level of populations. He has a special focus on longitudinal trajectory analyses and analysis of clustering of diabetic complications.

Professor Witte studied medicine and completed a PhD in clinical epidemiology at the University of Utrecht, the Netherlands, followed by 5 years as MRC clinical research fellow at the department of Epidemiology and Public Health, University College London. In January 2015 he was appointed Professor of Diabetes Epidemiology at Aarhus University. Professor Witte teaches national and international courses at the post-graduate level and supervises several PhD students.

Eran Segal, Professor

Weizmann Institute of Science

Eran Segal is a professor at Weizmann Institute of Science (IL), heading the Segal Lab with a team of computational biologists and experimental scientists. Professor Segal works on developing quantitative models for all levels of gene regulation, including transcription, chromatin, and translation. Professor Segal gained his BA in Computer Science and Economics from Tel Aviv University in 1998 and his PhD from Stanford University in 2004. In 2007 Professor Segal was awarded the Overton Prize by the International Society for Computational Biology.

Professor Segal's research focuses on the relationship between nutrition, health, and gut microbes in human individuals and his research group has extensive experience in machine learning, computational biology, probabilistic models, and analysis of heterogeneous high-throughput genomic data from various technologies such as next-generation sequencing. Professor Segal aims to develop personalized medicines based on big data from human cohorts, and Professor Segal is currently two years in with a cohort that has committed to 25 years. Professor Eran Segal recently joined BiInnovation Institute's Scientific Advisory Board.

Ewan Pearson, Professor

University of Dundee

Ewan Pearson is Professor of Diabetic Medicine at the University of Dundee (UK), Visiting Professor at the University of Edinburgh, and Honorary Consultant in Diabetes and Endocrinology at Ninewells Hospital and Medical School in Dundee. In the School of Medicine, he is the Head of Division for Population Health and Genomics and the Director of the Dundee Clinical Academic Track. Professor Pearson obtained his medical degree from the University of Cambridge School of Clinical Medicine and completed his PhD in the physiology and treatment of monogenic diabetes at the University of Exeter Medical School.

Professor Pearson's research interests have been in the phenotypic and genotypic determinants of drug response in diabetes, and in stratified approaches to the management of diabetes. Professor Pearson leads the IMI-DIRECT project on stratification in type 2 diabetes and is strand 2 lead on the ABPI-MRC funded MASTERMIND project. Professor Pearson has been awarded the Royal College of Physicians of Edinburgh Croom Lecture, an EASD Rising Star award, the Diabetes UK RD Lawrence Lecture and the EASD Minkowski Award for his work in these areas.

Giles Yeo, Dr.

University of Cambridge

Giles Yeo got his PhD from the University of Cambridge (UK) in 1997, after which he joined the lab of Professor Sir Stephen O'Rahilly, working on the genetics of severe human obesity. He is now a programme leader at the MRC Metabolic Diseases Unit in Cambridge, and his research currently focuses on the influence of genes on feeding behaviour and body weight. In addition, he is a graduate tutor and fellow of Wolfson College, and Honorary President of the British Dietetic Association. He is also a broadcaster and author, presenting science documentaries for the BBC, and hosts a podcast called 'Dr Giles Yeo Chews the Fat'. His first book, *Gene Eating*, was published in December 2018, and his second book, *Why Calories Don't Count*, came out in June 2021. He was appointed an MBE in the Queen's 2020 birthday honours for services to 'Research, Communication and Engagement'.

Henrik Ullum, CEO

Statens Serum Institut

Henrik Ullum has been the CEO of Statens Serum Institut (DK) since December 2020. Statens Serum Institut's goal is to strengthen health through disease control and research. Statens Serum Institut handles several key emergency preparedness tasks, in-

cluding prevention and control of infections, biological threats and congenital diseases. At the same time, Statens Serum Institut is one of Denmark's largest research institutions in health, and research is a priority for all of its core areas.

Henrik Ullum graduated as a Doctor of Medicine from the University of Copenhagen in 1994, from where he also obtained a PhD in 1998. He trained as a specialist in clinical immunology in 2004. From 2006 to 2020, he was Chief Physician at the Department of Clinical Immunology, Rigshospitalet (DK), as well as Professor at the Department of Clinical Medicine, University of Copenhagen between 2014 and 2020. He was also Chair of the Organisation of Danish Medical Societies (LVS) from 2015 to 2020. In this capacity, he was member of the national Danish Advisory Board for Personalised Medicine, board member of Programme for Clinical Research Infrastructure (PRO-CRIN), member of Strategic Alliance for Register and Health Data (STARS), and board member of the Danish Medical Association Research Fund. He organised through LVS a series of Danish national meetings in 2016 on personalised medicine, which fed into the formulation of the Danish national strategy for personalised medicine.

Hindrik Mulder, Editor-in-chief, Professor

Diabetologia, Lund University

Hindrik Mulder (MD, PhD) is a Professor of Metabolism at Lund University (S). He is also a practicing clinician, conducting a weekly outpatient clinic for diabetes patients at the Department of Endocrinology, Skåne University Hospital (S). He has for several years been vice-coordinator of EXODIAB, a national strategic research area in diabetes. In 2001, he was appointed Associate Professor and began establishing the Unit of Molecular Metabolism, which he leads to this day. He has devoted his research career to understanding the mechanisms of insulin secretion and why they fail in type 2 diabetes. To this end, he has developed metabolomics and imaging approaches to delineate metabolic events in beta cells and islets. More recently, he has elucidated how genetic variants associated with type 2 diabetes contribute to disease mechanisms; this involves signaling of melatonin. He has served as Senior and European Editor for the *Journal of Endocrinology*. Since 2021, he has been Editor in Chief of *Diabetologia* (US), Professor at Harvard Medical School (US), and an institute member at the Broad Institute of MIT and Harvard (US), where he co-directs the Metabolism Program and is active in the Program in Medical and Population Genetics.

He and his group have contributed to the performance and analysis of high-throughput genome-wide association and sequencing studies in type 2 diabetes and related traits, in the Diabetes Genetics Initiative, the Framingham Heart Study and other international consortia such as MAGIC, GENIE, DIAGRAM, T2D-GENES, SIGMA, AMP-T2D

and RADIANT, where he plays management roles. He leads the genetic research efforts of the Diabetes Prevention Program and the GRADE clinical trial, where the effects of genetic variants on the development of diabetes can be examined prospectively, and their impact on specific behavioural and pharmacological preventive interventions can be assessed. He is the Principal Investigator of the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) and conducts other pharmacogenetic studies at MGH. In addition to his research and teaching duties, he is clinically active in the MGH Diabetes Center, the Endocrine inpatient consult service, the Medicine service, and the Down Syndrome Program.

He serves on the Editorial Board for *Human Genetics*, and has been on Editorial Boards for *Diabetes*, *Diabetologia* and *Journal of Clinical Endocrinology and Metabolism*; he is also the Editor-in-Chief for *Current Diabetes Reports*.

Sir John Bell, Professor

Office for the Strategic Coordination of Health Research

Professor Sir John Bell is Regius Professor of Medicine at the University of Oxford (UK), and Chairman of Office for the Strategic Coordination of Health Research. He is Chairman of the Bill & Melinda Gates Foundation Global Health Advisory Board and sits on the board of Genomics England as a Non-Executive Director. He went to Oxford as a Rhodes Scholar to train in medicine and undertook postgraduate training in London and at Stanford University.

In 1993, he founded the Wellcome Trust Centre for Human Genetics, a leading international centre for complex trait common disease genetics. In 2008 he was made a Fellow of the Royal Society and was made a Knight Bachelor for his services to Medical Science. He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research and the life science industry. He served as President of the Academy of Medical Sciences from 2006 to 2011, and he was previously in the Board of Director of Roche Holding. His research interests lie in the area of autoimmune disease and immunology, where he has contributed to the understanding of immune activation in a range of autoimmune diseases.

Jose C. Florez, Professor

Harvard Medical School

Jose C. Florez is Chief of the Endocrine Division and Diabetes Unit at the Massachusetts General Hospital (US), Professor at Harvard Medical School (US), and an institute

member at the Broad Institute of MIT and Harvard (US), where he co-directs the Metabolism Program and is active in the Program in Medical and Population Genetics.

He and his group have contributed to the performance and analysis of high-throughput genome-wide association and sequencing studies in type 2 diabetes and related traits, in the Diabetes Genetics Initiative, the Framingham Heart Study and other international consortia such as MAGIC, GENIE, DIAGRAM, T2D-GENES, SIGMA, AMP-T2D and RADIANT, where he plays management roles. He leads the genetic research efforts of the Diabetes Prevention Program and the GRADE clinical trial, where the effects of genetic variants on the development of diabetes can be examined prospectively, and their impact on specific behavioral and pharmacological preventive interventions can be assessed. He is the Principal Investigator of the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) and conducts other pharmacogenetic studies at MGH. In addition to his research and teaching duties, he is clinically active in the MGH Diabetes Center, the Endocrine inpatient consult service, the Medicine service, and the Down Syndrome Program.

He serves on the Editorial Board for *Human Genetics*, and has been on Editorial Boards for *Diabetes*, *Diabetologia* and *Journal of Clinical Endocrinology and Metabolism*; he is also the Editor-in-Chief for *Current Diabetes Reports*.

Juleen R. Zierath, Professor

Karolinska Institutet and University of Copenhagen

Juleen R. Zierath is a native of Milwaukee Wisconsin. She is Professor of Experimental Physiology at Karolinska Institutet, Stockholm (S) and Professor of Integrative Physiology and Executive Director at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen (DK). She performs translational research to delineate mechanisms for the development of insulin resistance in Type 2 diabetes. Current work is focused on the role of epigenetic modifications in the development of insulin resistance and the interaction between circadian rhythms and exercise training in the control of metabolism.

She is a member of the Nobel Assembly and Nobel Committee for Physiology or Medicine, and a Member of the Royal Swedish Academy of Science and Academia Europaea. She has previously been Chair of the Nobel Committee, and is former President of the European Association for the Study of Diabetes. She is past Editor-in-Chief of *Diabetologia* and currently holds editorial positions with several scientific journals in the fields of endocrinology, metabolism, and interdisciplinary sciences. She has received the Claude Bernard Medal and Lectureship from the European Association for the Study of Diabetes, the Datta Lectureship Award for outstanding

achievement from the Federation of European Biochemical Society, the Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes, the Knud Lundbaek Award from the Scandinavian Society for the Study of Diabetes, J.B. Wolffe Memorial Lectureship Award from the American College of Sports Medicine, The Nordic Medicine Prize for Research in Diabetes, and a Distinguished Alumnus Award and Honorary Doctorate of Science from University of Wisconsin-River Falls.

Kari Stefansson, CEO

deCODE

Kari Stefansson, MD, PhD is a founder and CEO of the Icelandic biotechnology company deCODE genetics. He pioneered the use of population genetics in the study of human diversity. The population approach he advanced in Iceland has served as a model for large-scale genome projects around the world. Before founding deCODE in 1996, he was a professor of neurology, neuropathology and neuroscience at Harvard Medical School (US). He is an International Member of the US National Academy of Sciences, a member of the European Molecularbiology Organization (EMBO) and the recipient of the American Society of Human Genetics (ASHG) William Allan Award, the European Society of Human Genetics Award, the Anders Jahre Award, the Federation of European Biomedical Societies Sir Hans Krebs Medal, the European Heart Association Gold Medal, the World Glaucoma Association Award, the American Alzheimer's Association's Inge Grundke-Iqbal Award, the Wallace H. Coulter Distinguished Award, International KFJ Award from Rigshospitalet in Denmark, and the Jakobus Award. Kari Stefansson was chosen by *Time Magazine* as one of the 100 most influential men of the year for 2007 (Time100 list for 2007), as one of the 10 most important biologists of the 21 century by *Newsweek* in 2007, as one of the stars of Europe at the forefront of change by *BusinessWeek* in 2000, appeared on the Reuter's/Thompson's list of the world's 10 most cited scientists of 2010, Clarivate Analytics 2016, 2017 and 2018 Highly Cited Researcher in molecular biology and genetics, Clarivate Analytics 2019 and 2020 Highly Cited Researcher Cross-Field.

Louis H. Philipson, Professor

University of Chicago

Louis H. Philipson is Director of the Kovler Diabetes Center and James C. Tyree Professor of Diabetes Research and Care in the Departments of Medicine and Pediatrics at the University of Chicago (US). He served as President, Medicine and Science for the American Diabetes Association (ADA) in 2019-2020 and has served twice as a member of its National Board. Currently, he is a member of the ADA steering committee for the Precision Diabetes Medicine initiative.

After attending Harvard College, his further training (PhD in Biochemistry, MD) and faculty positions have all been at the University of Chicago. His career first focused on cellular and translational studies related to insulin secretion. He has contributed to basic research in the control of insulin secretion via ion channels and calcium regulation in pancreatic beta cells. His current research focuses on genetic causes of diabetes, atypical diabetes, and prevention of type 1 diabetes. He and his colleagues Drs. Bell, Greeley and Naylor have a leading centre for monogenic diabetes in the United States (<http://monogenicdiabetes.uchicago.edu>). The team established the first United States registry for neonatal and monogenic diabetes, and currently he is a coPI and member of the steering committee for a multicentre NIDDK programme to identify atypical forms of diabetes (the RADIANT study). He maintains a multidisciplinary clinic focused on type 1 diabetes and monogenic diabetes for children and adults. He received the Banting medal for service as part of the 79th Annual Scientific Sessions (2019) for his term as President for Medicine and Science. In 2018 he was inducted as a laureate of the Lincoln Academy of Illinois, the highest civilian honour of the State of Illinois.

Mads Krogsgaard Thomsen, CEO

Novo Nordisk Foundation

Mads Krogsgaard Thomsen graduated from the University of Copenhagen in 1986, where he later also obtained his PhD and DSc degrees within the pharmacology of experimental therapeutics. After three years of pharmacological research at Leo Pharma, he joined Novo Nordisk A/S where he was head of Growth Hormone research, Diabetes R&D, Global Drug Discovery and, since 2000, Executive Vice President and Chief Science Officer. In this role, he was responsible for global drug and device research, CMC and global development, medical affairs, regulatory and safety within Novo Nordisk. During his tenure, 20 innovative medicines were developed and approved. On 1 March 2021, he was appointed CEO of the Novo Nordisk Foundation.

He has chaired Danish Research Council programmes within endocrinology and served as President of the Danish Academy of Technical Sciences. He has been board member of the Danish Technical University, Cellartis AB, Steno Diabetes Center, Symphogen A/S and Chairman of the Board of the University of Copenhagen, Denmark. Today, he serves as member of the board of BB Biotech, Switzerland. He is also a member of the editorial boards of international, peer-reviewed journals. Since 2000, he has served as Adjunct Professor of Pharmacology at the Life Sciences Faculty of Copenhagen University. At a national level, he has acted as Chairman of the Danish Biotech, Research and Innovation Centre during its establishment, as well as on governmental committees, e.g., related to revision of the Danish system for post-graduate

studies. His scientific publications include books, chapters and scientific papers within pharmacology, immunology, endocrinology, and haemostasis.

Maria F. Gomez, Professor

Lund University

Maria F. Gomez is Professor of Physiology at the Department of Clinical Sciences, Lund University (S) and Director of the Lund University Diabetes Centre.

After medical school, she completed her PhD in Physiology at Lund University (1998) and post-doctoral studies at the Pharmacology Department, University of Vermont (2001). For the past 20 years, her laboratory has focused on mechanisms leading to diabetic complications, with the aim to discover new targetable signalling pathways and develop new medicinal products. She coordinates IMI2 project BEAt-DKD (Biomarker Enterprise Attacking Diabetic Kidney Disease), a unique public-private partnership focused on identifying drug-targetable disease pathways and biomarkers of disease progression and treatment response in patients with DKD. She was the scientific coordinator of efforts leading to the generation of several novel animal models of diabetic complications that better replicate human disease during IMI1 project SUMMIT. Together with Paul Franks and Tove Fall, she led the COVID Symptom Study in Sweden, a not-for-profit initiative that was launched in March 2020 to support vital COVID-19 research, and which today is the world's largest ongoing study of COVID-19 with over 4.6 million contributors globally. By combining reports that participants submit daily via an app with software algorithms, they can predict who has the virus and track COVID infections across Sweden. The daily reporting is also being used to generate new scientific understanding of the very different symptoms the virus causes in different people, as well as to study the way that risks vary between individuals because of their own personal characteristics.

Marie-France Hivert, Associate Professor

Harvard Medical School

Marie-France Hivert is an Associate Professor in the Department of Population Medicine at Harvard Pilgrim Health Care Institute and Harvard Medical School (US). She is a clinical investigator with a primary focus on the aetiology and primordial prevention of obesity and related co-morbidities, particularly type 2 diabetes and gestational diabetes. Her interests also include foetal metabolic programming mechanisms and the integration of genetics, epigenetics, and environmental factors contributing to obesity and related disorders. She completed her clinical training as an Endocrinologist in 2007 at the Université de Sherbrooke, and a postdoctoral fellowship at the Massachusetts General Hospital and a Master's in Medical Sciences in the Scholars in Clinical

Sciences Program at Harvard Medical School in 2009. Associate She moved to the Department of Population Medicine at HMS in 2013, leading research projects in observational prospective pre-birth cohorts and in intervention studies in the peri-pregnancy period. From 2009 to 2013 she also built and directed the Lifestyle Medicine course for the medical school curriculum at Universite de Sherbrooke to allow better training in lifestyle counselling of future physicians. At Harvard Medical School, she has been a teaching faculty member in the Clinical Epidemiology and Population Health course since 2014 and involved in the nutrition education committee since 2015. Nationally, she has been part of the Lifestyle Medicine education collaborative and is currently a member of the American Heart Association's Lifestyle Council Leadership committee.

Marit Eika Jørgensen, Professor

Steno Diabetes Center Greenland

Marit Eika Jørgensen is a Senior Physician at the Steno Diabetes Center Greenland. She is a Professor in Arctic Health, University of Southern Denmark, and Adjunct Professor at the University of Greenland. She is a Specialist in Endocrinology and Internal Medicine, with a Doctor of Medicine and a Doctor of Philosophy from the University of Copenhagen.

She is actively engaged in epidemiological research with a focus on the association between social transition, lifestyle factors, genetics, environmental factors, and chronic disease, primarily diabetes, obesity, and cardiovascular disease. Her current research involves population surveys of the Greenlandic population, where she aims to study diabetes and cardiovascular disease. In Denmark, she has recently established a national diabetes register, to monitor diabetes prevalence, incidence, and complications. With the recent advances in availability of individually linked un-biased information on diabetes-related health, based on clinically collected data and register-compiled information, she aims to bridge the two sources of information on a solid quantitative background.

Martin Ridderstråle, Senior Vice President

Novo Nordisk Foundation

Martin Ridderstråle, Senior Vice President of Clinical Science and Chief Medical Officer at the Novo Nordisk Foundation, oversees the Foundation's activities relating to the creation and continued function of the Steno Diabetes Centres in the five regions of Denmark and in Greenland, and support to clinical science through the committees for Clinical and Translational Medicine, Steno Collaborative Grants, Non-Diabetic Endocrinology Collaborative Grants, and Nursing Research.

Martin Ridderstråle is an MD, specialist in Endocrinology and Diabetology as well as in Internal Medicine, and has a PhD in Molecular Signalling from Lund University in Sweden, where he has also been Adjunct Professor of Endocrinology, and an MBA from Copenhagen Business School. Martin Ridderstråle has worked as Head of the Department of Endocrinology as well as Deputy Head of the Division of Specialised Medicine at Skåne University Hospital in Sweden, and Vice President and Head of Clinic at Steno Diabetes Center in Gentofte. Before joining the Novo Nordisk Foundation, he was working as Corporate Vice President of Clinical Pharmacology and Translational Medicine at Novo Nordisk A/S.

Michael Lynge Pedersen, Chief Medical Officer.

Steno Diabetes Center Greenland

Michael Lynge Pedersen is a specialist in general medicine at the Greenland Center for Health Research, University of Greenland. He has a doctorate in diabetes management from Aarhus University (DK). Dr. Lynge Pedersen's research field concerns human health in Greenland with a focus on lifestyle diseases and conditions including epidemiology and management in the health care system based on register surveys. Dr. Lynge Pedersen's doctoral dissertation described the use of a new model for diabetes care in Greenland, and how to ensure that diabetes patients receive the best treatment and knowledge about their disease, despite living far away from medical care.

Dr. Lynge Pedersen is the Chief Medical Director at Steno Diabetes Center Greenland. Furthermore, he is an Adjacent clinical associate professor at Greenland Center for Health Research in Greenland, Institute of Nursing and Health Science, University of Greenland. Dr. Lynge Pedersen is a member of the Board of the Society of Greenlandic Medicine, Greenland division since 2011, as well as a member of the Greenlandic Health Research Council, ministry of Health, Government of Greenland since 2012.

Michael Roden, Professor

Heinrich-Heine University, EFSD Scientific Board

Michael Roden is Chair and Full Professor of Internal Medicine, Endocrinology and Metabolic Disorders at Heinrich-Heine University (GE). Furthermore, Professor Roden is Director of the Division of Endocrinology and Diabetology at the University Clinics Düsseldorf and Chief Scientific Executive Officer of the German Diabetes Center (DDZ). Since 2017 Professor Roden has been Speaker of the Committee Medicine of

the German Council of Science and Humanities, which advises the President and Federal Government of Germany. Professor Roden was previously head of the 1. Medical Department of the Teaching Hospital of Medical University of Vienna, Hanusch Hospital, Max-Kade Fellow at Yale University, USA, and Associate Professor at University of Vienna, Austria. Professor Roden was President of the Central European and Austrian Diabetes Associations, and currently serves as Member of the Board of the European Foundation for the Study of Diabetes (EFSD) and the Board of European Association for the Study of Diabetes (EASD).

Professor Roden contributed paradigm-shifting concepts to insulin resistance and energy metabolism in diabetes and non-alcoholic fatty liver disease. Professor Roden currently serves on the editorial boards of *Mol Metab* and *Am J Physiol*. He received several awards, including the International Novartis Award (2004), ESCI Award (2006), Oskar-Minkowski Prize (2006), Paul-Langerhans Medal (2017) and the G. B. Morgagni Prize-Gold Medal Career Achievement (2018). He was also awarded honorary doctorates by the Medical School of the National & Kapodistrian University of Athens and by the Medical Faculty of the University of Belgrade.

Miriam S. Udler, Assistant Professor

Harvard Medical School

Miriam Udler is Assistant Professor of Medicine at Harvard Medical School and Director of the Massachusetts General Hospital Diabetes Genetics Clinic (US), seeing patients with rare genetic forms of diabetes. She specialises in treating endocrine disorders, with a particular focus on endocrine clinical genetics and atypical forms of diabetes. She received an AB degree cum laude from Harvard College, an MPhil and PhD from University of Cambridge, and an MD from University of Massachusetts Medical School. She completed a residency in Internal Medicine at Mount Sinai Hospital Medical Center, NY, and an endocrinology fellowship at Massachusetts General Hospital.

She is also an associate member of the Broad Institute of MIT and Harvard, and an NIH-funded researcher. Her research focuses on genetic contribution to diabetes risk and clinical applications of genomic data, including cluster analysis to identify disease pathways and genetic subtypes. She is interested in the impact of both common and rare genetic variation, and in the integration of clinical data from electronic health records. Additionally, she serves on ClinGen's expert panel for Maturity Onset Diabetes of the Young (MODY) and lectures nationally on monogenic diabetes.

Nynne Bjerre Christensen, Journalist

Freelance

Nynne Bjerre Christensen is a journalist graduated from the Danish School of Journalism in 1999 and has an MA in European Studies from King's College London (2003). She has for several years worked as a freelancer for, among others, *Månedstidende*, the European Commission and *Berlingske Tidende*, while also doing reportage trips to conflict and post-conflict areas such as Lebanon, Sri Lanka, and the Kurdish part of Turkey.

From 2005 to 2017, she hosted the daily news magazine *Deadline* on the television channel DR2, which has made her a very experienced moderator. Furthermore, she has moderated conferences in both Danish and English for more than ten years.

Paul W. Franks, Scientific Director, Professor

Novo Nordisk Foundation

Paul Franks is the Scientific Director in Clinical Science at the Novo Nordisk Foundation, where his main responsibilities involve developing and implementing clinically impactful precision medicine initiatives, as well as securing successful development of world-class prevention and treatment of diabetes, obesity, and non-diabetes endocrine diseases. In 2003 he obtained a PhD in Genetic Epidemiology from the Institute of Public Health, University of Cambridge (UK). In 2010, he was appointed Professor of Genetic Epidemiology at Lund University (S), and Adjunct Professor at the Harvard School of Public Health in Boston (US). In Lund, he led the Genetic and Molecular Epidemiology Unit and was deputy director of Lund University Diabetes Centre. He currently co-chairs the ADA/EASD Precision Medicine in Diabetes Initiative. He was previously the Vice-President Elect of the Nordic Society of Human Genetics and Precision Medicine and the co-lead of the Genomic Medicine Sweden Complex Trait Initiative. He has received awards from the European Association for the Study of Diabetes, Association for the Study of Obesity, American Colleges of Sports Medicine, European Commission, and other organisations for his research relating to precision medicine. He has also served on many advisory panels including those for the UK Medical Research Council, Genome Canada, US National Institutes of Health, World Health Organization etc., as well as for biotech and pharmaceutical companies. He has also served on the editorial boards of several journals, including *Diabetologia*, *Hypertension*, *BMC Medical Genomics* and *Obesity*. He has published extensively on topics germane to precision medicine in cardiometabolic diseases, including papers led by him or his students in *Nature*, *Science*, *New England Journal of Medicine* and *Nature Medicine*.

Ronald Ma, Professor

Chinese University of Hong Kong

Ronald Ma is Professor and Head of Division of Endocrinology and Diabetes, Department of Medicine and Therapeutics, as well as Assistant Dean of Faculty of Medicine at the Chinese University of Hong Kong. Professor Ma is the Co-director of Chinese University of Hong Kong – Shanghai Jiao Tong University Joint Research Centre in Diabetes Genomics and Precision Medicine and in the Steering Committee of Hong Kong Institute of Diabetes and Obesity. He completed his medical training at the University of Cambridge (UK), and trained in Internal Medicine in London. He subsequently returned to Hong Kong, where he completed his endocrinology fellowship training, followed by a research fellowship at the Joslin Diabetes Center, Harvard Medical School. Professor Ma's research interests include the epidemiology and genetics of diabetes and its complications, gestational diabetes, and the developmental origins of diabetes. He has contributed to the understanding of diabetes in Asians and is the principal investigator of the newly established Hong Kong Diabetes Biobank. Professor Ma plays an active role in diabetes advocacy. He is a past President of the International Diabetes Epidemiology Group (IDEG) and has served on the World Health Organization (WHO) Working Group on Science and Evidence to End Childhood Obesity (ECHO), and the Lancet Commission on Diabetes. Among others, Professor Ma currently serves as a member of the Executive Board, the Asian Association for the Study of Diabetes (AASD).

Ruth Loos, Professor

University of Copenhagen

Ruth Loos is the Vice Executive Director and Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen (DK). Furthermore, she is the Director of the Genetics of Obesity and Related Metabolic Traits Program and Professor of Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai (US).

Her research focuses on the aetiology of obesity and on the identification of genes and genetic loci contributing to the risk of obesity and related traits. By identifying genes, she aims to gain insight into the biology that underlies body weight regulation and the mechanisms that link adiposity to its comorbidities. She has been involved in gene discovery since 2005. With the GIANT (Genetic Investigation of ANthropometric traits) consortium, she has contributed to the majority of large-scale gene-discovery efforts that thus far have revealed more than 500 obesity-associated loci. Furthermore, she studies more refined adiposity phenotypes and biomarkers to target the deeper layers that define "obesity" and to fully capture all aspects of the biology involved. Besides gene-discovery, she uses epidemiological methods to assess the role

of genetic information in precision medicine of common obesity by examining its value in identifying subtypes of obesity, in predicting who is at risk of gaining weight, and in tailoring prevention and treatment strategies.

Stefano Del Prato, President

The European Foundation for the Study of Diabetes

Stefano Del Prato, MD, is Professor of Endocrinology and Metabolism at the School of Medicine, University of Pisa and Chief of the Section of Diabetes, University Hospital of Pisa (I). He graduated from the University of Padova (I) and undertook postgraduate specialisation in Endocrinology and Internal Medicine. He has been Associate Professor of Medicine at the University of Texas, San Antonio, TX (US). His main research interests have always been the physiopathology and therapy of type 2 diabetes and insulin resistance.

He is President of the EASD and the EFSD, past President and Honorary President of the Italian Society of Diabetology and member of many other societies and associations including the American Diabetes Association. He acts as referee for numerous journals and has served on the Editorial Boards of major scientific journals in the field of diabetes and metabolism. He has been awarded several honours including the Prize of the Italian Society of Diabetology for outstanding scientific activity and the Honorary Professorship at the Universidad Peruana Cayetano Heredia in Lima.

Sir Stephen O’Rahilly, Professor

University of Cambridge

Stephen O’Rahilly is Professor of Clinical Biochemistry and Medicine and Head of the Department of Clinical Biochemistry at the University of Cambridge (UK), where he also directs the MRC Metabolic Diseases Unit in the Wellcome-MRC Institute of Metabolic Science. He qualified in Medicine from University College Dublin and continued his post-graduate training at Oxford University and Harvard Medical School. In 1991, he joined the faculty at Cambridge University, studying human metabolic and endocrine diseases. He is known for his work in identifying novel extreme human metabolic phenotypes and identifying genes important in metabolic function and dysfunction. His research has led to an increased understanding of the genetic causes of human obesity and insulin resistance. Using modern biochemical approaches and classical clinical observation in humans with profound metabolic disorders, he has shown that a person’s appetite and feeding behaviour can be linked to specific genes. The work has challenged long-held dogmas and led to new treatment avenues.

He was elected as a fellow of the Academy of Medical Sciences (1999), and the Royal Society (2003) and is also an international member of the National Academy of Sciences (2011). He was knighted in the Queen's 2013 Birthday Honours for services to medical research and was the 2019 Banting Medal Recipient for Scientific Achievement of the American Diabetes Association.

Søren Brunak, Professor

University of Copenhagen

Søren Brunak is a Danish physicist and biological researcher working with bioinformatics, systems biology, and health informatics. He is Professor of Disease Systems Biology at the University of Copenhagen and Professor of Bioinformation at the Technical University of Denmark, as well as a Medical Informatics Officer at Rigshospitalet (DK).

In 1993, he became the founding director of the Center for Biological Sequence Analysis (CBS) at the Technical University of Denmark (DTU), heading a multi-disciplinary research group of molecular biologists, biochemists, medical doctors, physicists, and computer scientists. In 2007, he became one of the founding research directors at the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen. His programme for Disease Systems Biology combines molecular level systems biology and the analysis of phenotypic data from the healthcare sector. In 2011, he was also one of the founders of the Novo Nordisk Foundation Center for Biosustainability at DTU, where he led the Section for Metagenomic Systems Biology until 2013. He has been a member of the Royal Swedish Academy of Sciences since 2016, a member of the European Molecular Biology Organization since 2009, and a member of the Royal Danish Academy of Sciences and Letters since 2004.

Tina Blichfeldt, person with diabetes

Steno Diabetes Center Copenhagen

Tina Blichfeldt has a Master Degree in international business from Southbank University in London where she lived and worked for 11 years and was connected to the diabetes clinic at Kings College Hospital. Tina is partner in Blichfeldt Invest and has simultaneously been fundraising for the American Juvenile Diabetes Research Foundation and has been a member of the JDRF Board in Denmark. Furthermore, Tina is teaching medical students and nurses at Rigshospitalet, Copenhagen in regard to communication, interdisciplinary cooperation and digitalization from a user perspective.

Tina Blichfeldt was diagnosed in 1974 with type 1 diabetes and has been a user of Århus Kommunehospital, Hvidøre Hospital in Copenhagen and since 1991 (though, with 11 years in the UK) at Steno Diabetes Center Copenhagen which offer world-class

treatment in diabetes in Denmark.

Based on her relation to the Steno Diabetes Center Copenhagen and being a member of the Novo Nordisk, Disease Experience Expert Panel (DEEP) Tina became member of the steering committee for user involvement in 2017 as a user representative as part of the intensified focus on user involvement at Steno Diabetes Center Copenhagen with the aim to strengthen decision-making and development processes. Tina has on behalf of Steno Diabetes Center Copenhagen furthermore participated as a user representative at the Self-Management Diabetes Alliance in Glasgow (2019) and in Stockholm (2020) and at the CODIAC2021 conference in October in Copenhagen centering on the impact and values of user involvement.

Tina has been focusing on the mental aspect of living with diabetes and how the choices of medicine and devices and how the use of flourishing communication has a significant impact on the treatment of diabetes. Equally the focus has been on the opportunity to create strong peer-to-peer support to share knowledge and aspects of the everyday life with diabetes.

Torben Hansen, Professor

University of Copenhagen

Torben Hansen is Professor of Molecular Metabolism and Director of the Programme Human Genomics and Metagenomics in Metabolism and the Hansen Group, Genomic Physiology and Translation at the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen (DK). Here, he leads investigations on the human genome and the human global microbiome to characterise the impact of these genomes on health and disease and to identify interactions between the host and the microbiome. He is also involved in pre- and postgraduate educational activities at the Universities of Copenhagen, Aarhus, and Odense. Since 2005, he has collaborated with Steno Diabetes Center in Copenhagen on molecular genetic diagnostics of monogenic forms of diabetes and obesity.

He graduated with an MD from the University of Copenhagen in 1984 and obtained his PhD from the University of Copenhagen in 1992. His major research interests are the pathophysiology and pathogenesis of type 2 diabetes, obesity and the metabolic syndrome, and the identification of genetic determinants for both mono and polygenic components of diabetes and obesity. Furthermore, his recent research is also focused on the impact of the gut and saliva microbiome on disease and health and the crosstalk between the host genome and the microbiome.

Thomas R. Pieber, Professor

Medical University of Graz

Thomas Pieber is Professor of Medicine, Chair of the Division of Endocrinology and Diabetology at the Department of Internal Medicine at the Medical University of Graz (AT). He is also Director of the Institute of Biomedicine and Health Sciences at Joanneum Research in Graz, and founder of CBmed, a competence centre for biomarker research. He and his group have developed and tested several new therapeutic concepts for type 1 and type 2 diabetes, from new pharmacological interventions to innovative medical devices, and developed strategies for disease prevention and carried out research in the field of integrative care and outcome research. He has been serving as principal investigator (PI) in several international study groups and multicentre trials funded by the EU Commission and foundations, such as JDRF and LRA in the USA. In basic research, he and his team investigate the role of metabolism in aging and β -cell resilience.

He has written more than 450 original papers and reviews in peer-reviewed journals. He is a member of the International Working Group on the Diabetic Foot and a member of the Cochrane Review Group “Endocrine and Metabolic Diseases”. Furthermore, he serves as reviewer or advisor for international journals and funding organisations.

